Business Wire

LUMINATI

23.7.2019 10:02:11 CEST | Business Wire | Press release

Share
Frost & Sullivan Names Luminati the 2019 Global Market Leader in the Enterprise IP Proxy Networks Market

Luminati , the Israeli company that allows businesses to experience the web through the eyes of individual consumers throughout the world, today announced it has received a Market Leadership Award in the first independent analysis of the sector. Luminati’s enterprise IP proxy network (IPPN) services for global retailers, brand owners and advertising networks feature strongly in the report by analyst firm Frost & Sullivan. The report outlines a relatively new, but rapidly growing market and recognizes Luminati’s leading position in the provision of solutions that are increasingly important for businesses to remain competitive and compliant in the digital landscape. [S1]

The market for enterprise IP proxy network solutions is in its early growth stages, basically being invented by Luminati only a few years ago. With the more specialized targeting of customers by demographics and location, companies are finding it more difficult than ever to do competitive analysis and verify advertising, security, and website performance. Companies not familiar with these website practices or Internet Protocol proxy network (IPPN) solutions are at risk of gathering incorrect data and left behind technology-wise,” noted Robert Cavin, Industry Analyst, Digital Media, Frost & Sullivan.

All online businesses today rely on the market data they harvest from the Web - retailers need pricing and offers comparisons, global brands need to check and manage how their products are presented and ad networks need to verify compliance. Unfortunately, with an increasingly personalized and geo-targeted Web, searching for that data from one, or even multiple locations is unlikely to deliver any meaningful business intelligence. A once transparent and open Web has become increasingly opaque.

Luminati gives back that transparency by shedding light on what’s really going on beneath the surface of the web. Luminati’s Enterprise IP Proxy Network (IPPN) harnesses the IP addresses of over 35 million opted-in end-users worldwide to provide businesses with a real and accurate view of the web, exactly how actual consumers see it, at every geographic location. By seeing the web from any perspective, without being blocked or misled, businesses can protect their brand, research competitors, monitor for security issues, test ads and ultimately maintain a competitive edge.

The Frost & Sullivan report is encouraging reading, not only for Luminati, but as a means to alert the market to the potential for access to unique data and intelligence ,” said Or Lenchner, Luminati CEO . “Ours is a relatively new industry, but one that is bringing back transparency to the Web. Ironically, the technologies that are now universally deployed to personalize the user experience are also used to severely limit legitimate research .”

That research helps companies around the world to compete on a level playing field, verify brand presentation, gather public data, test application performance, and limit fraud. That can only be a good thing in a global market but it’s critical that companies work with a responsible provider of IPPN services to protect their own reputation ,” continued Lenchner.

Frost & Sullivan’s report names Luminati the 2019 global market leader in the Enterprise IP Proxy Network market, and acknowledges how the company has revolutionized the technology through its residential peer-to-peer network. What’s more, the analysis identifies Luminati’s technical leadership and strict adherence to compliance procedures as factors that will likely cement the company’s leadership position over the coming years.

Key findings from the Frost & Sullivan report include:

  • Despite the need amongst enterprises for competitor analysis, price comparison and data gathering, a significant proportion of the market is not aware of IPPN services – they risk losing revenue and customers to those businesses taking advantage of the benefits the technology delivers
  • Luminati’s services currently account for more than half of global revenues; the company is positioned as the market leader based on penetration, product line and competitive strategy
  • The top five use cases for enterprise IPPN by revenue (2018) are:
    • Price comparison
    • Ad verification
    • Fraud protection
    • Data collection
    • Brand protection
  • Revenues are expected to reach nearly USD $260M by 2025

-ENDS-

About Luminati

Founded in 2014, Luminati is the world’s largest proxy service, aimed at bringing complete transparency back to the internet. The company’s first-of-its-kind enterprise IP proxy network (IPPN) enables businesses to level the global competitive landscape by collecting online data that may otherwise mislead them, or they may be blocked from accessing.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works collaboratively with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye